Loading...
XPAR
DIM
Market cap23bUSD
Dec 04, Last price  
214.00EUR
1D
-0.56%
1Q
23.17%
Jan 2017
256.85%
Name

Sartorius Stedim Biotech SA

Chart & Performance

D1W1MN
XPAR:DIM chart
P/E
118.87
P/S
7.49
EPS
1.80
Div Yield, %
0.32%
Shrs. gr., 5y
0.98%
Rev. gr., 5y
14.05%
Revenues
2.78b
+0.16%
484,301,000521,053,000268,836,000367,996,000401,231,000432,949,000477,300,000543,964,000588,378,000683,524,000884,331,0001,051,611,0001,081,033,0001,212,152,0001,440,570,0001,910,081,0002,886,977,0003,492,700,0002,775,500,0002,780,000,000
Net income
175m
-43.46%
22,026,00029,019,0004,742,00013,104,00029,092,00038,511,00043,190,00056,756,00066,276,00072,472,000117,999,000153,678,000161,088,000208,052,000234,574,000335,932,000414,400,000876,100,000309,700,000175,100,000
CFO
815m
+29.44%
43,852,00051,715,00026,021,00047,226,00091,855,00072,759,00060,593,00048,927,00090,106,000111,312,000142,789,000156,659,000174,689,000227,289,000310,129,000416,879,000695,971,000612,300,000629,700,000815,100,000
Dividend
Apr 02, 20240.69 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
IPO date
Oct 20, 1994
Employees
11,135
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT